The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6 –11 with cystic fibrosis in a real-world setting

Data from clinical trials of lumacaftor-ivacaftor (LUM-IVA) demonstrate improvements in lung clearance index (LCI) but not in FEV1 in children with Cystic Fibrosis (CF) aged 6 –11 years and homozygous for the Phe5...

Source: Respiratory Research - August 11, 2023 Category: Respiratory Medicine Authors: Paul McNally, Barry Linnane, Michael Williamson, Basil Elnazir, Christopher Short, Clare Saunders, Laura Kirwan, Rea David, Mariette P. C. Kemner-Van de Corput, Harm A.W.M. Tiddens, Jane C Davies and Des W Cox Tags: Research Source Type: research